Barclays Maintains Overweight on Abivax, Raises Price Target to $148

Benzinga Newsdesk www.benzinga.com Positive 79.5%

Neg 0% Neu 0% Pos 79.5%

Barclays analyst Etzer Darout maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $142 to $148.